Pharmacokinetics of gallium maltolate after intragastric administration in adult horses

American Journal of Veterinary Research

Volumn 71, Issue 11, 2010, Pages 1371-1376

  Arnold, Carolyn ^a   Chaffin, M Keith ^a   Cohen, Noah ^a   Fajt, Virginia R ^a   Taylor, Robert J ^a   Bernstein, Lawrence R ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b Terrametrix   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM; GALLIUM MALTOLATE; UNCLASSIFIED DRUG;

ADOLESCENT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HORSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BONE DISEASES; FEMALE; GALLIUM; HORSE DISEASES; HORSES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; ORCHIECTOMY; ORGANOMETALLIC COMPOUNDS; PYRONES;

ANIMALIA; EQUIDAE;

EID: 78149397611     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.71.11.1371     Document Type: Article

References (27)

1. Wilsher S, Allen WR, Wood JL. Factors associated with failure of Thoroughbred horses to train and race. Equine Vet J 2006;38:113-118.
2. Rossdale PD, Hopes R, Digby NJ, et al. Epidemiological study of wastage among racehorses 1982 and 1983. Vet Rec 1985;116:66-69.
3. Bailey CJ, Rose RJ, Reid SW, et al. Wastage in the Australian Thoroughbred racing industry: a survey of Sydney trainers. Aust Vet J 1997;75:64-66.
4. Kaneene JB, Ross WA, Miller RA. The Michigan equine monitoring system. II. Frequencies and impact of selected health problems. Prev Vet Med 1997;29:277-292.
5. Russell RG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999;14(suppl 2):53-65.
6. David P, Nguyen H, Barbier A, et al. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res 1996;11:1498-1507.
7. Murakami H, Takahashi N, Tanaka S, et al. Tilduronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 1997;20:399-404.
8. Reginster JY. Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992;13:351-354.
9. Kamm L. McIlwraith W, Kawcak C. A review of the efficacy of tiludronate in the horse. J Equine Vet Sci 2008;28:209-214.
10. Denoix JM, Thibaud D, Riccio B. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. Equine Vet J 2003;35:407-413.
11. Denoix JM. Efficacy of tiludronate, a new bisphosphonate, in the treatment of navicular disease and bone spavin. A multicentric European clinical trial. Ipologia 2002;13:7-9.
12. Delguste C, Amory H, Doucet M, et al. Pharmacological effects of tiludronate in horses after long-term immobilization. Bone 2007;41:414-421.
13. Coudry V, Thibaud D, Riccio B, et al. Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column. Am J Vet Res 2007;68:329-337.
14. Warrell RP Jr, Isaacs M, Coonley CJ, et al. Metabolic effects of gallium nitrate administered by prolonged infusion. Cancer Treat Rep 1985;69:653-655.
15. Warrell RP Jr, Bockman RS, Coonley CJ, et al. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 1984;73:1487-1490.
16. 3+ contrasts with bisphosphonate metabolic suppression: competitive inhibition of H+ ATPase by bone-bound gallium. J Bone Miner Res 1991;6(suppl 1):S127.
17. Bockman RS, Guidon PT Jr, Pan LC, et al. Gallium nitrate increases type I collagen and fibronectin mRNA and collagen protein levels in bone and fibroblast cells. J Cell Biochem 1993;52:396-403.
18. Guidon PT Jr, Salvatori R, Bockman RS. Gallium nitrate regulates rat osteoblast expression of osteocalcin protein and mRNA levels. J Bone Miner Res 1993;8:103-112.
19. Stern LS, Matkovic V, Weisbrode SE, et al. The effect of gallium nitrate on an osteopenia induced by ovariectomy and a low-calcium diet in rats. Bone Miner 1994;25:59-69.
20. Newman RA, Brody AR, Krakoff IH. Gallium nitrate (NSC-15200) induced toxicity in the rat: a pharmacologic, histopathologic and microanalytical investigation. Cancer 1979;44:1728-1740.
21. Berstein LR. Therapeutic gallium compounds. In: Gielen M, Tiekink ER, eds. Metallotherapeutic drugs and metal-based diagnostic agents: the use of metals in medicine. Chichester, West Sussex, England: John Wiley & Sons, 2005;259-277.
22. Bernstein LR, Tanner T, Godfrey C, et al. Chemistry and pharmacokinetics of gallium maltolate, a compound with high oral gallium bioavailability. Met Based Drugs 2000;7:33-47.
23. Martens RJ, Mealey K, Cohen ND, et al. Pharmacokinetics of gallium maltolate after intragastric administration in neonatal foals. Am J Vet Res 2007;68:1041-1044.
24. Chaffin MK, Fajt V, Martens RJ, et al. Pharmacokinetics of an orally administered methylcellulose formulation of gallium maltolate in neonatal foals. J Vet Pharmacol Ther 2010;33:376-382.
25. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978;6:165-175.
26. Blair HC, Teitelbaum SL, Tan HL, et al. Reversible inhibition of osteoclastic activity by bone-bound gallium (III). J Cell Biochem 1992;48:401-410.
27. Bockman RS, Wilhelm F, Siris E, et al. A multicenter trial of low dose gallium nitrate in patients with advanced Paget's disease of bone. J Clin Endocrinol Metab 1995;80:595-602.